LLY
Eli Lilly and Company
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 30.6B | 16.8B | 8.8B | 4.2B | 7.6B | 7.4B | 6.5B | 4.8B | 5.5B | 5.6B | 4.9B | 3.0B | 4.5B | 5.7B | 5.3B | 7.2B | 6.9B | 4.3B | 7.3B | 5.2B |
| 11.0B | 7.8B | 5.1B | 3.4B | 1.9B | 1.3B | 1.4B | 1.0B | 1.2B | 1.1B | 1.0B | 1.1B | 1.2B | 1.0B | 905M | 672M | 694M | 765M | 947M | 1.1B | |
| Free cash flow | 19.7B | 9.0B | 3.8B | 792M | 5.7B | 6.1B | 5.1B | 3.8B | 4.3B | 4.5B | 3.8B | 1.9B | 3.3B | 4.7B | 4.4B | 6.6B | 6.2B | 3.6B | 6.3B | 4.1B |
| Depreciation and amortization | 2.17B | 2.00B | 1.77B | 1.53B | 1.52B | 1.55B | 1.32B | 1.23B | 1.61B | 1.57B | 1.50B | 1.43B | 1.38B | 1.45B | 1.46B | 1.37B | 1.33B | 1.30B | −1.12B | −1.05B |
| Stock-based compensation | 698M | 626M | 646M | 629M | 371M | 343M | 308M | 312M | 280M | 281M | 255M | 218M | 156M | 145M | 142M | 147M | 231M | 369M | −255M | −282M |
| Buybacks | 5.84B | 4.11B | 2.50B | 0.75B | 1.50B | 1.25B | 0.50B | 4.40B | 4.15B | 0.30B | 0.60B | 0.75B | 0.80B | 1.70B | 0.72B | 0 | 0 | — | — | — |
| Dividends paid | 5.98B | 5.38B | 4.68B | 4.07B | 3.54B | 3.09B | 2.69B | 2.41B | 2.31B | 2.19B | 2.16B | 2.13B | 2.10B | 2.12B | 2.19B | 2.18B | 2.17B | 2.15B | 2.06B | 1.85B |
| Dividends per share | — | 6.23 | 5.40 | 4.69 | 4.07 | 3.53 | 3.07 | 2.68 | 2.33 | 2.12 | 2.05 | — | — | — | — | 1.96 | 1.96 | 1.96 | 1.90 | — |
| Free cash flow margin | 22.7% | 13.8% | 8.3% | 2.3% | 20.1% | 21.4% | 20.8% | 17.0% | 20.1% | 22.7% | 18.0% | 9.5% | 16.8% | 20.4% | 19.5% | 27.0% | 26.7% | 16.4% | 31.2% | 21.9% |